What does "AI visibility" mean for my business?

When someone asks ChatGPT, Claude, or Gemini "what is the best..." or "where can I find...", AI gives specific recommendations. AI visibility is a measure of how often — and how positively — these AI platforms mention your business. It's the new version of being on the first page of Google, except now there are no pages — just one answer.

Which AI platforms do you monitor?

Pendium monitors ChatGPT, Claude, Gemini, Grok, Perplexity, DeepSeek, and Google AI Overviews — seven major AI platforms that consumers use to research local services. We run real queries that your customers actually ask and analyze the responses for mentions of your business, competitors, and industry topics.

How does Pendium improve my visibility?

Three ways. First, we identify the exact queries and topics where you're invisible. Second, we generate AI-optimized content — articles, guides, social posts — designed to help AI agents understand your business and recommend your services to the right people. Third, we continuously monitor to track improvement and find new opportunities. Most clients see measurable improvement within 60 days.

How long until I see results?

You'll get your first visibility report within minutes of signing up. Actual visibility improvement varies, but our clients typically see a 47% average improvement within 60 days. Some see results faster — it depends on your current online presence and how competitive your local market is.

Do I need to be technical to use this?

Not at all. Enter your website URL and Pendium handles everything: scanning AI platforms, analyzing your visibility, generating content, and tracking improvement. The dashboard is designed for business owners, not engineers. If you can check your email, you can use Pendium.

What makes this different from SEO?

Traditional SEO optimizes for Google's search rankings — blue links on a results page. AI visibility is different: AI doesn't show links, it gives direct answers. Even if you rank #1 on Google, ChatGPT might recommend a competitor. Pendium optimizes for the new paradigm — making sure AI platforms know about, trust, and recommend your business.

Pricing

Get a demo

NewLimit

Visibility47

Vibe86

Businesses/Biotechnology/NewLimit

AI Visibility & Sentiment

NewLimit

NewLimit is a clinical-stage biotechnology company focused on the field of longevity by developing epigenetic reprogramming medicines. By utilizing proprietary machine learning and genomics, they aim to restore youthful function to aging cells to treat and prevent various chronic age-related diseases.

Active Monitoring

newlimit.com

Biotechnology Startups

AI Visibility Score

47/100

Moderate

Sentiment Score

86/100

Score by Reach

How often this business is recommended to users across different types of conversations — from direct product queries to broader open-ended conversations where AI could recommend this company's products and services

core

adjacent

aspirational

visionary

AI Perception

Key Takeaways

How AI platforms collectively perceive and describe NewLimit today.

NewLimit has successfully cemented its status as a trusted authority for users seeking specific brand validation, yet it remains largely absent from the broader, intent-driven conversations that shape industry leadership. While the brand dominates niche inquiries regarding its own identity, it is currently ceding significant influence to competitors like Altos Labs and Unity Biotechnology within critical longevity and clinical research discourses.

Value Proposition

NewLimit utilizes a unique 'partial reprogramming' approach that restores the youthful function of cells while maintaining their original identity, powered by an AI-driven platform that screens transcription factor combinations at high speed.

Overview

Mission

To significantly extend human healthspan by developing epigenetic reprogramming medicines to treat age-related diseases.

Products & Services

Liver Rejuvenation ProgramImmune Rejuvenation ProgramVascular Program targeting endothelial cellsProprietary Discovery Platform for AI and functional genomics

Current State

Visibility Landscape

A high-level view of how NewLimit performs across AI platforms, broken down by strategic reach level — from core brand queries to growth opportunities.

	ChatGPT	Claude	Gemini	AI Overviews
Reputation Brand recognition & direct queries	—	91	45	0
Core Topics Product/service category queries	—	—	34	—
Growth Areas Adjacent, aspirational & visionary	—	—	0	—

ChatGPT

Claude

Gemini

AI Overviews

Reputation

Brand recognition & direct queries

—

Core Topics

Product/service category queries

—

Growth Areas

Adjacent, aspirational & visionary

—

Competitive Landscape

Altos Labs

18 mentions

Life Biosciences

8 mentions

Retro Biosciences

8 mentions

Unity Biotechnology

7 mentions

BioAge Labs

7 mentions

Prenuvo

6 mentions

Loading visibility matrix...

Analysis

Insights & Recommended Actions

What's working, what's not, and specific steps to improve NewLimit's AI visibility.

Key Findings

Strength

High brand recall and authority within 'vibe check' queries on Gemini, consistently appearing in the top position.

Strength

Effective resonance with the 'Academic Clinical Investigator' persona, where NewLimit captures top-tier placement for specialized inquiries.

Strength

Strong performance in localized niches related to immune system rejuvenation and functional genomics.

Recommended Actions

Develop comprehensive, authoritative content mapping the technical rigor of longevity biotech, specifically targeting comparative research queries.

Competitors are currently dominating these broader discussions; creating comparative frameworks will force search engines to associate NewLimit with industry leaders.

Implement a 'thought leadership' initiative targeting the 'Preventative Health & Lifestyle' persona.

The brand is currently invisible in this category, which is a massive missed opportunity to capture users interested in the practical applications of longevity science.

Optimize technical documentation and research summaries to address the 'vetting' criteria identified in clinical-stage research queries.

By aligning the brand’s digital footprint with the specific indicators researchers use to evaluate biotech, NewLimit will move from being a 'vibe check' result to a standard-bearer for clinical trust.

Content Engineering

Content Ideas

Content designed to help AI agents learn about your category and recommend your brand.

Programmatic Testing

Sample Conversations

We programmatically analyze questions that real customers are asking to AI agents and chatbots, extract brand mentions and sentiment, analyze every response, and synthesize the data into an action plan to increase AI visibility.

ChatGPT

Claude

Gemini

AI Overviews

Longevity & Healthspan Intervention Research(3 queries)

“what are the most promising clinical-stage companies working on liver rejuvenation right now”

1/3 platforms mentioned

Core

Claude

1.Life Biosciences (PER, ER-300, ER-100)

2.LyGenesis

3.NewLimit

4.Resolution Therapeutics (RTX001)

5.HepaRegeniX

+3 more

Gemini

1.LyGenesis (LYG-LIV-001)

2.HepaRegeniX (HRX-215)

3.Akero Therapeutics (Efruxifermin)

4.89bio (Pegozafermin)

5.Alentis Therapeutics (Lixudebart)

+2 more

AI Overviews

1.HepaRegeniX (HRX-215)

2.Resolution Therapeutics (RTX001)

3.Gwo Xi Stem Cell (GXHPC1)

4.Inventiva (lanifibranor)

5.Life Biosciences

+3 more

“best companies to look at for immune system rejuvenation and epigenetic reprogramming therapy”

1/1 platforms mentioned

Core

Gemini

1.Altos Labs

2.Life Biosciences (ER-100)

3.Turn Biotechnologies (ERA)

4.NewLimit

5.Retro Biosciences

+8 more

“compare the approaches of biotech firms focusing on vascular endothelial cell health”

0/1 platforms mentioned

Core

Gemini

1.Microvascular Health Solutions (BioRegenx, Endocalyx Pro)

2.GlycoCalyx Research Institute (GlycoCheck, ReVasca)

3.Vascugen

4.BioGenCell

5.Aurion Biotech

+5 more

Source Intelligence

Citations

The sources AI platforms cite when recommending this brand. Pendium reverse-engineers what's already proven to be catnip to AI agents, then engineers content that fills gaps and helps agents do their job — which means more citations for you.

Life Biosciences Presents New Data at ARDD 2025 on the Company’s Partial Epigenetic Reprogramming Platform in Liver and Ocular Diseases

lifebiosciences.com

NewLimit

Key Takeaways

Visibility Landscape

Insights & Recommended Actions

Content Ideas

Sample Conversations

Citations

Competitive Landscape

Brand Voice & Style

Investors

Engineer content that makes AI agents recommend you

Explore Biotechnology

Start getting recommended by AI

Frequently asked questions